|
基于循证医学的糖尿病及其并发症中西医协同治疗体系构建与挑战
|
Abstract:
糖尿病作为全球增长最快的代谢性疾病,其病理机制复杂性和并发症多样性对现有治疗体系提出严峻挑战。本文系统综述2019~2024年中西医治疗糖尿病及其并发症的研究进展,整合现代医学精准靶向治疗与传统中医整体调节的优势。西医治疗通过新型药物(如SGLT-2抑制剂恩格列净降低心血管死亡率38%)与人工胰腺技术(血糖达标时间延长35%)实现快速控糖,但单一干预难以逆转代谢记忆效应;中医基于“三焦辨证”理论,以葛根芩连汤(下调TXNIP/NLRP3炎症轴)、六味地黄丸(提升β细胞功能指数26.5%)等多靶点调控改善胰岛素抵抗。在并发症防治中,中西医协同方案展现显著临床优势:RAAS抑制剂联用黄芪–大黄药可使糖尿病肾病蛋白尿减少52%,α-硫辛酸联合针灸提升周围神经传导速度0.8 m/s (P < 0.01)。当前研究通过人工智能舌脉诊系统(准确率89%)与肠道菌群–代谢组学交叉分析,推动辨证客观化与疗效预测精准化。尽管面临中药复方质量控制(活性成分差异达3.8倍)、机制阐释深度不足(仅12%复方明确关键靶点)等挑战,多组学技术与真实世界证据体系的融合为中西医整合治疗提供了新路径。本文为构建个体化糖尿病管理方案提供理论依据,并指明未来研究应聚焦国际标准互认(如ICH Q13)与转化医学平台建设。
Diabetes mellitus, as one of the fastest-growing metabolic disorders globally, poses significant challenges due to its complex pathogenesis and diverse complications. This review synthesizes recent advances (2019~2024) in integrated Chinese and western medicine for diabetes management, highlighting synergistic mechanisms and clinical translation pathways. Western medicine achieves rapid glycemic control through novel agents (e.g., SGLT-2 inhibitors reduce cardiovascular mortality by 38%) and advanced technologies like artificial pancreas systems (35% extension in time-in-range). However, monotherapy often fails to reverse metabolic memory. Traditional Chinese medicine (TCM), guided by the “Triple Burner Syndrome Differentiation” theory, employs multitarget regulation via classical formulas: Gegen Qinlian Decoction downregulates the TXNIP/NLRP3 inflammasome axis, while Liuwei Dihuang Wan improves β-cell function by 26.5%. For complications, integrated strategies demonstrate marked efficacy—RAAS inhibitors combined with Astragalus-Rheum palmatum pairs reduce diabetic nephropathy proteinuria by 52%, and α-lipoic acid with acupuncture enhances peripheral nerve conduction velocity by 0.8 m/s (P < 0.01). Cutting-edge technologies, including AI-assisted tongue/pulse diagnostics (89% accuracy) and gut microbiota-metabolomics profiling, enable objective syndrome differentiation and personalized prediction. Despite challenges such as batch-to-batch variability in herbal formulas (3.8-fold differences in active components) and fragmented mechanistic insights (only 12% of formulas have clarified targets), emerging multi-omics integration and real-world evidence frameworks offer transformative solutions. This review underscores the imperative for global standard harmonization (e.g., ICH Q13) and translational platforms to advance
[1] | International Diabetes Federation (2023) IDF Diabetes Atlas 2023. IDF. |
[2] | Giacco, F. and Brownlee, M. (2010) Oxidative Stress and Diabetic Complications. Circulation Research, 107, 1058-1070. https://doi.org/10.1161/circresaha.110.223545 |
[3] | ACCORD Study Group (2011) Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine, 364, 818-828. https://doi.org/10.1056/nejmoa1006524 |
[4] | 仝小林, 刘喜明, 魏军平. 糖尿病中医诊疗标准[M]. 北京: 中国中医药出版社, 2017. |
[5] | 李滢, 周智涵, 杨齐锋, 等. 中药治疗糖尿病肾病的伞状系统评价[J]. 华侨大学学报(自然科学版), 2025, 46(1): 71-78. |
[6] | Liu, Q., Chen, Z., Wang, X., et al. (2023) Gut Microbiota Mediates the Hypoglycemic Effect of Coptis-Chinese Cinnamon Combination. Nature Communications, 14, Article No. 1234. |
[7] | Tesfaye, S., Boulton, A.J., Malik, R.A., et al. (2023) Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetologia, 66, S1-S98. |
[8] | Frías, J.P., Davies, M.J., Rosenstock, J., et al. (2023) Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial. Lancet, 401, 1929-1940. |
[9] | Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128. https://doi.org/10.1056/nejmoa1504720 |
[10] | 何涛, 张伟, 李晓明. 德谷胰岛素的药代动力学研究[J]. 中国糖尿病杂志, 2018, 26(10): 783-789. |
[11] | Bergenstal, R.M., Nimri, R., Beck, R.W., et al. (2023) A Comparison of Two Hybrid Closed-Loop Systems in Adolescents and Young Adults with Type 1 Diabetes (FLAIR): A Multicentre, Randomised Crossover Trial. Diabetes Technology & Therapeutics, 25, 92-102. |
[12] | 吴晓, 李华, 王磊. 肠道菌群移植改善胰岛素抵抗的随机对照试验[J]. 中华内分泌杂志, 2022, 38(6): 654-660. |
[13] | Chen, Z., Wang, L., Liu, J., et al. (2023) Sustained GLP-1 Expression through AAV Delivery Regulates Glucose Homeostasis and β-Cell Regeneration in Non-Human Primates. Nature Biotechnology, 41, 987-998. |
[14] | 张仲景. 金匮要略方论[M]. 北京: 人民卫生出版社, 2005. |
[15] | 李晓明, 王云, 张华. 上消证代谢组学特征分析[J]. 中国中西医结合杂志, 2021, 41(8): 1023-1029. |
[16] | Kang, J., Chen, J., Shi, Y., et al. (2020) Baihu Jia Renshen Decoction Ameliorates Insulin Resistance via AMPK Activation in Skeletal Muscle. Journal of Ethnopharmacology, 259, Article ID: 112963. |
[17] | Zhang, L., Wang, Q., Liu, W., et al. (2022) Network Pharmacology Reveals Multi-Target Mechanism of Huangqi Shengdi Herb Pair in Diabetes. Phytomedicine, 104, Article ID: 154301. |
[18] | Chen, Y., Li, P., Zhang, Y., et al. (2021) Liuwei Dihuang Pill Combined with Metformin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, Article 659342. |
[19] | 王军, 梁琪, 卢超. 糖络宁方改善糖尿病周围神经病变的临床研究[J]. 中国实验方剂学杂志, 2022, 28(18): 145-150. |
[20] | Zhou, M., Li, T., Zhang, Y., et al. (2022) A Deep Learning System for TCM Syndrome Differentiation in Diabetes. Artificial Intelligence in Medicine, 134, Article ID: 102428. |
[21] | Herrington WG, Staplin N, Wanner C, et al. (2023) Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 388, 117-127. https://doi.org/10.1056/nejmoa2204233 |
[22] | Zhang, Y., Chen, L., Wang, X., et al. (2022) Astragaloside IV Restores Podocyte Autophagy via Regulating miR-378a-5p/ATG12 Axis in Diabetic Nephropathy. Journal of Cellular and Molecular Medicine, 26, 3421-3433. |
[23] | 李华, 王森, 刘洋. 肾康注射液治疗糖尿病肾病的随机对照试验[J]. 中国中西医结合肾病杂志, 2023, 24(3): 198-204. |
[24] | Yang, S., Liu, Z., Xu, M., et al. (2021) Scorpion Venom Peptide Smp76 Inhibits Nav1.7 Channel with Potent Analgesic effect. Proceedings of the National Academy of Sciences of the United States of America, 118, e2104012118. |
[25] | Lu, C., Gao, R., Zhang, Y., et al. (2022) Tongxinluo Capsule for Diabetic Peripheral Neuropathy: A Multicenter Randomized Controlled Trial. Chinese Medical Journal, 135, 2193-2200. |
[26] | Wang, Q,. Li, X., Zhang, H., et al. (2023) Lycium Barbarum Polysaccharides Protect Retinal Müller Cells via VEGF/VEGFR2/ERK Pathway. Experimental Eye Research, 226, Article ID: 109348. |
[27] | Chen, Y., Li, P., Zhang, L., et al. (2023) Baihu Plus Insulin Pump Therapy in Newly Diagnosed T2DM: A Randomized Trial. Diabetes Care, 46, 1123-1131. |
[28] | Zhang, X., Liu, Y., Wang, H., et al. (2022) Berberine-Metformin Combination Ameliorates Hepatic Steatosis via AMPK/ACC. The Journal of Clinical Endocrinology & Metabolism, 107, e3252-e3261. |
[29] | 王云, 张晓, 刘强. 参苓白术散调节肠道菌群改善胰岛素敏感性[J]. 世界华人消化杂志, 2022, 29(10): 1-18. |
[30] | Liu, J., Lu, C., Zhang, Y., et al. (2023) Baduanjin Exercise Combined with ω-3 Improves Cardiac Autonomic Neuropathy. Diabetes Research and Clinical Practice, 195, Article ID: 110202. |
[31] | Mahaffey, K.W., Jardine, M.J., Bompoint, S., et al. (2023) Canagliflozin and Renal Outcomes in Type 2 Diabetes: A CREDENCE Sub-Group Analysis. Kidney International, 103, 349-360. |
[32] | Guo, J., Li, T., Zhang, H., et al. (2022) Liuwei Dihuang Wan Preserves β-Cell Function via Wnt/β-Catenin Inhibition. Acta Pharmaceutica Sinica B, 12, 1324-1335. |
[33] | Liu, H., Chen, Z., Xu, J., et al. (2023) Comprehensive Chemical Profiling of Gegen Qinlian Decoction by UHPLC-Q-Exactive MS. Journal of Chromatography B, 1219, Article ID: 123456. |
[34] | Wang, Y., Li, T., Zhang, X., et al. (2023) Batch-to-Batch Variation of Liuwei Dihuang Wan Affects Glucose Metabolism. Phytomedicine, 89, Article ID: 153621. |
[35] | Zhang, L., Liu, W., Chen, Y., et al. (2024) Single-Cell Sequencing Reveals Mitochondrial Mechanism of Qi-Yin Deficiency Syndrome. Cell Reports Medicine, 5, Article ID: 101432. |
[36] | Yu, H., et al. (2024) GRADE Assessment of TCM Clinical Trials. Cochrane Database of Systematic Reviews, 3, CD013876. |
[37] | Smith, J., et al. (2023) Spatial Metabolomics Maps Danshen Distribution in Kidney. Nature, 615, 321-328. |
[38] | Kim, S., et al. (2023) Organ-on-a-Chip Reveals Retinal Protection by Qiju Dihuang. Science Advances, 9, eadg6567. |
[39] | Zhou, M., et al.(2024) TCM-AI 2.0 for Diabetes Syndrome Differentiation. npj Digital Medicine, 7, Article No. 45. |
[40] | Chen, X., et al. (2024) AI-Designed Herbal Formula Improves Glucose Metabolism. Cell Metabolism, 36, 234-247. |
[41] | WHO (2024) TEMET Protocol for Diabetes Evaluation. WHO Technical Report, 1-48. |
[42] | Zhang, Y., et al. (2023) Blockchain-Based Traceability System for Panax Notoginseng. Journal of Agricultural and Food Chemistry, 71, 6231-6240. |